Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986315
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral, Intravenous
01
Overview
BMS-986315 is a fully human IgG1.3 monoclonal antibody developed as an immunotherapy for cancer. It specifically targets and antagonizes the natural killer group 2 member A (NKG2A), a checkpoint receptor expressed on natural killer (NK) cells and some T lymphocytes. By blocking NKG2A, BMS-986315 is designed to enhance the immune system’s ability to recognize and destroy tumor cells through mechanisms such as antibody-dependent cell cytotoxicity. The drug was primarily investigated in advanced solid tumors, including non-small cell lung cancer (NSCLC), renal cell carcinoma, and head and neck squamous cell carcinoma—both as monotherapy and in combination with other agents like nivolumab or cetuximab[1][2][6][7].
- Other names
- anti-NKG2A monoclonal antibodyanti-NKG-2A monoclonal antibodyanti-NKG 2A monoclonal antibody
02
Targets
KLRC1 (Killer cell lectin-like receptor subfamily C member 1)
Beyond the preview
Go deeper on BMS-986315.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986315.